Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species

Bianco, Gabriele; Boattini, Matteo; Comini, Sara; Gaibani, Paolo; Cavallo, Rossana; Costa, Cristina

doi:10.1007/s10096-024-04745-7

Cited by 3 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the performance of cefiderocol susceptibility testing represents an additional challenge to its use in clinical practice for CRAB infections. Disc diffusion appears to be a valid method of determining susceptibility ( 15 ), while EUCAST has issued warning against use of certain broth microdilution platforms for determining cefiderocol susceptibility ( 16 ). Cefiderocol and sulbactam readily penetrate the CSF in patients with bacterial meningitis and significant inflammation ( 10 , 17 , 18 ).…”

Section: Discussionmentioning

confidence: 99%

Case report: Successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy

Snowdin,

Mercuro,

Madaio

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Meningitis caused by Acinetobacter species is a rare complication of neurosurgical procedures, although it is associated with high morbidity and mortality. Carbapenem-resistant Acinetobacter is particularly difficult to treat, considering the limited selection and tolerability of effective antimicrobials. Sulbactam-durlobactam was approved by the FDA in 2023 for treatment of hospital-acquired and ventilator-associated pneumonia due to susceptible strains of Acinetobacter, including carbapenem-resistant Acinetobacter baumannii. Here, we present a case of carbapenem-resistant Acinetobacter baumannii neurosurgical infection and meningitis successfully treated with sulbactam-durlobactam combination therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Case report: Successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy

Snowdin,

Mercuro,

Madaio

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

Cefiderocol – An effective antimicrobial for MDR infections but a challenge for routine antimicrobial susceptibility testing

Brauncajs,

Bielec,

Macieja

et al. 2024

Advances in Medical Sciences

View full text Add to dashboard Cite

Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains

Jean-Pierre,

Sorlin,

Pantel

et al. 2024

Ann Clin Microbiol Antimicrob

View full text Add to dashboard Cite

Background Achromobacter spp. are opportunistic pathogens, mostly infecting immunocompromised patients and patients with cystic fibrosis (CF) and considered as difficult-to-treat pathogens due to both intrinsic resistance and the possibility of acquired antimicrobial resistance. Species identification remains challenging leading to imprecise descriptions of resistance in each taxon. Cefiderocol is a broad-spectrum siderophore cephalosporin increasingly used in the management of Achromobacter infections for which susceptibility data remain scarce. We aimed to describe the susceptibility to cefiderocol of a collection of Achromobacter strains encompassing different species and isolation sources from CF or non-CF (NCF) patients. Methods We studied 230 Achromobacter strains (67 from CF, 163 from NCF patients) identified by nrdA gene-based analysis, with available susceptibility data for piperacillin–tazobactam, meropenem and trimethoprim–sulfamethoxazole. Minimal inhibitory concentrations (MICs) of cefiderocol were determined using the broth microdilution reference method according to EUCAST guidelines. Results Strains belonged to 15 species. A. xylosoxidans represented the main species (71.3%). MICs ranged from ≤ 0.015 to 16 mg/L with MIC50/90 of ≤ 0.015/0.5 mg/L overall and 0.125/2 mg/L against 27 (11.7%) meropenem-non-susceptible strains. Cefiderocol MICs were not related to CF/NCF origin or species although A. xylosoxidans MICs were statistically lower than those of other species considered as a whole. Considering the EUCAST non-species related breakpoint (2 mg/L), 228 strains (99.1%) were susceptible to cefiderocol. The two cefiderocol-resistant strains (A. xylosoxidans from CF patients) represented 3.7% of meropenem-non-susceptible strains and 12.5% of MDR strains. Conclusions Cefiderocol exhibited excellent in vitro activity against a large collection of accurately identified Achromobacter strains, irrespective of species and origin.

show abstract

Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species

Cited by 3 publications

References 19 publications

Case report: Successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy

Case report: Successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy

Cefiderocol – An effective antimicrobial for MDR infections but a challenge for routine antimicrobial susceptibility testing

Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains

Contact Info

Product

Resources

About